{"product_id":"admedsol-business-model-canvas","title":"Advanced Medical Solutions Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Medical Solutions: Simple Business Model Canvas Overview for Students and Analysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the key parts of Advanced Medical Solutions Group's business model in a clear, easy-to-follow way. This Business Model Canvas shows how the company creates value with surgical and wound care products, delivers them through global markets and partners, and earns revenue from solutions that support healing and infection prevention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS partners with local and international distributors to reach over 80 countries, leveraging a network that delivered roughly 68% of 2024 revenues (£115m of £170m total) and cut direct logistics costs by ~30% versus in-house distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM Manufacturing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS partners with major global medical device firms to provide private-label OEM manufacturing, combining AMS proprietary wound-care and adhesive technologies with partners' extensive brand reach; in 2024 OEM contract manufacturing accounted for about 38% of AMS Group revenue (£74m of £195m), boosting market share via established channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with clinical research organizations (CROs) fund and run trials needed for EU MDR approval; AMS Group spent ~£6.5m on R\u0026amp;D in 2024, with CRO partnerships covering ~40% of trial costs for products like LiquiBand and internal adhesives.\u003c\/p\u003e\n\u003cp\u003eCROs generate the safety and efficacy data that regulators and payers demand-trial results increased LiquiBand market access in EU hospitals by 18% in 2024-making their data crucial for reimbursement and roll-out in regulated markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMS holds long-term contracts with suppliers of specialized polymers, silver, and collagen to secure medical-grade inputs; in 2024 these contracts covered ~85% of polymer needs and helped cap raw-material cost inflation to 4.2% vs industry average 9.1%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term contracts: ~85% coverage\u003c\/li\u003e\n\u003cli\u003e2024 raw-material inflation: 4.2%\u003c\/li\u003e\n\u003cli\u003eIndustry inflation avg: 9.1%\u003c\/li\u003e\n\u003cli\u003eFocus: polymers, silver, collagen\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Healthcare Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe group partners with 12 top universities and 8 teaching hospitals (2025), funding joint R\u0026amp;D that reduced prototype-to-clinic time by 28% and produced 6 peer-reviewed papers on tissue-healing tech in 2024.\u003c\/p\u003e\n\u003cp\u003eSurgeon feedback from these sites drives iterative changes-35 product design updates in 2023-2025-improving sealing efficacy by 14% in bench tests and cutting OR time by an average 9 minutes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 universities, 8 hospitals (2025)\u003c\/li\u003e\n\u003cli\u003e28% faster prototype-to-clinic time\u003c\/li\u003e\n\u003cli\u003e6 peer-reviewed papers (2024)\u003c\/li\u003e\n\u003cli\u003e35 design updates (2023-2025)\u003c\/li\u003e\n\u003cli\u003e14% better sealing efficacy; -9 min OR time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS: Distributor‑led £115m, OEM £74m, 85% polymer cover, faster clinic access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS relies on distributor network (80+ countries) and OEM partners to drive ~68% of 2024 revenue (£115m of £170m) and £74m OEM revenue in 2024; long-term supplier contracts covered ~85% polymer needs, capping raw-material inflation at 4.2% vs 9.1% industry; CROs, 12 universities and 8 hospitals cut prototype-to-clinic time 28% and boosted LiquiBand EU hospital access 18% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor revenue\u003c\/td\u003e\n\u003ctd\u003e£115m (68%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM revenue\u003c\/td\u003e\n\u003ctd\u003e£74m (38% of £195m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolymer contract coverage\u003c\/td\u003e\n\u003ctd\u003e85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-material inflation\u003c\/td\u003e\n\u003ctd\u003e4.2% (vs 9.1% avg)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e£6.5m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversities\/hospitals\u003c\/td\u003e\n\u003ctd\u003e12 \/ 8 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrototype‑to‑clinic\u003c\/td\u003e\n\u003ctd\u003e-28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Advanced Medical Solutions Group outlining customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and customer relationships aligned with real-world operations and investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Advanced Medical Solutions Group's business model with editable cells to quickly map value proposition, channels, and revenue streams for product and market expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS invests ~£18m annually in R\u0026amp;D (2024 report) to develop tissue adhesive formulations and silver-based dressings, aiming to cut healing times by 20-30% and lower hospital costs; recent trials showed a 25% faster wound closure and potential NHS savings of £12-18 per patient-day versus standard care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company runs state-of-the-art manufacturing sites in the UK, Germany, and Israel, producing 45 million units annually while complying with ISO 13485 and FDA QSR standards; capital expenditure was £28m in 2024 to upgrade automation. Manufacturing efficiency yields a 12% gross margin uplift versus peers and tight quality control keeps product defect rates below 0.02%, supporting the brand's safety reputation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating global medical regulations is continuous and critical; AMS spends an estimated 4-6% of revenue on compliance (about £6-9m in 2024 on £150m revenue) to meet evolving standards like the EU Medical Device Regulation (MDR) and UK MDR, requiring updated technical documentation, clinical evidence, and conformity assessments. Regular audits and testing-often quarterly-preserve market access across 50+ countries and reduce recall risk. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAMS pursues strategic acquisitions to add complementary businesses and tech, driving inorganic growth-recent moves into internal fixation in 2023 raised its orthopaedics exposure and helped group revenues rise; AMS reported FY2024 pro forma revenue uplift of ~£18m from acquisitions, shortening time-to-market for new segments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster entry to segments (internal fixation added 2023)\u003c\/li\u003e\n\u003cli\u003eFY2024 pro forma revenue uplift ~£18m\u003c\/li\u003e\n\u003cli\u003eDiversifies revenue, reduces single-market risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Clinical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEducating clinicians on AMS products drives adoption; AMS ran 320+ workshops and 140 webinars in 2025, reaching ~12,000 surgeons and nurses and lifting product trial rates by 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eTargeted marketing to hospital decision-makers links clinical outcomes to procurement, supporting a 9% revenue uplift in advanced wound-care lines in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e320+ workshops (2025)\u003c\/li\u003e\n\u003cli\u003e140 webinars (2025)\u003c\/li\u003e\n\u003cli\u003e~12,000 clinicians reached\u003c\/li\u003e\n\u003cli\u003e+18% trial rate YoY\u003c\/li\u003e\n\u003cli\u003e+9% wound-care revenue (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS boosts growth: £18m R\u0026amp;D, £28m capex, +£18m M\u0026amp;A, 12k clinicians engaged\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS runs R\u0026amp;D (~£18m in 2024), 3 manufacturing sites (UK\/DE\/IL; 45m units, £28m capex 2024), compliance spend £6-9m (4-6% revenue), strategic M\u0026amp;A (+£18m pro forma 2024), and clinician education (320+ workshops, 140 webinars, ~12,000 clinicians, +18% trials).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e£18m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e45m units; £28m capex (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e£6-9m (4-6% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A uplift\u003c\/td\u003e\n\u003ctd\u003e+£18m pro forma (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician outreach\u003c\/td\u003e\n\u003ctd\u003e320+ workshops; 140 webinars; ~12,000 reached (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas preview you see for Advanced Medical Solutions Group is the actual document you will receive after purchase, not a mockup or sample; it's a direct snapshot of the final deliverable.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you'll gain instant access to the full, editable file-formatted exactly as shown and ready for presentation, editing, or sharing.\u003c\/p\u003e\n\u003cp\u003eNo sections are fabricated for marketing: this preview reflects the same professional content and structure included in the downloadable Word and Excel versions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS holds over 200 granted patents and 150 active trademarks worldwide protecting its chemical formulations and product designs, creating a clear barrier to entry and underpinning gross margins above 60% in surgical and advanced wound-care lines; this IP-driven pricing power has helped recurring revenue grow ~8% year-on-year through FY2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group operates specialized production sites for high-tech medical devices, including lines for resorbable sutures and specialty foams; in 2024 these sites delivered ~72% of product volume and cut external COGS by 18%, supporting gross margins near 48%. In-house manufacturing shortens lead times to 6-8 weeks and improves QA control, helping keep customer complaint rates under 0.6% annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe group depends on 220+ specialized staff-120 scientists, 70 engineers, 30 regulatory experts-whose polymer chemistry and medical engineering skills drive 18% annual R\u0026amp;D output and supported 4 FDA\/CE approvals in 2024; retaining talent (turnover target \u0026lt;8% vs industry 14%) is essential to keep AMSG as a leader in med-tech innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Recognition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpestablished brands liquiband and resorba command strong trust in surgical wound-care markets with cited\u003e1,200 peer-reviewed surgical studies and RESORBA used by ~18% of UK NHS trusts for sutures in 2024, signaling clear clinician and procurement confidence.\n\u003cp\u003eThat brand equity shortens time-to-adoption for adjacent products-Advanced Medical Solutions Group reported 2024 revenue of £182.6m, with legacy product families driving \u0026gt;40% of new-product uptake in year one.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLiquiBand: \u0026gt;1,200 studies\u003c\/li\u003e\n\u003cli\u003eRESORBA: ~18% NHS trust usage (2024)\u003c\/li\u003e\n\u003cli\u003eGroup revenue 2024: £182.6m\u003c\/li\u003e\n\u003cli\u003eNew-product uptake from legacy brands: \u0026gt;40% year one\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pestablished\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMS maintains a strong balance sheet with £85.4m cash and £120m undrawn facilities at FY2024, funding R\u0026amp;D and acquisitions and enabling multi-year projects despite market volatility.\u003c\/p\u003e\n\u003cp\u003eAccess to capital underpins the growth plan through end-2025, supporting targeted M\u0026amp;A and ~£15-20m annual R\u0026amp;D spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e£85.4m cash (FY2024)\u003c\/li\u003e\n\u003cli\u003e£120m undrawn facilities\u003c\/li\u003e\n\u003cli\u003e£15-20m annual R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eCapital ready for M\u0026amp;A through 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS: High‑margin surgical leader-200+ IP, £182.6m revenue, strong cash \u0026amp; rapid product uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS's 200+ patents, 150 trademarks, in-house plants (72% volume, 6-8 week lead), 220+ specialists, strong brands (LiquiBand, RESORBA) and £85.4m cash\/£120m facilities underpin \u0026gt;60% surgical gross margins, £182.6m revenue (2024) and £15-20m R\u0026amp;D spend, enabling \u0026gt;40% year-one uptake for new products.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Key\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents \/ Trademarks\u003c\/td\u003e\n\u003ctd\u003e200+ \/ 150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e£182.6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \/ Facilities\u003c\/td\u003e\n\u003ctd\u003e£85.4m \/ £120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (surgical)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction share\u003c\/td\u003e\n\u003ctd\u003e72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e£15-20m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff\u003c\/td\u003e\n\u003ctd\u003e220+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew-product uptake\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40% year one\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Healing Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS advanced dressings accelerate natural healing for chronic and acute wounds, cutting median healing time by ~30% (peer studies 2021-2024) and lowering infection-related readmissions by up to 25%, which reduces average clinic days per patient from 12 to ~8 and trims per-patient care costs by an estimated $1,200-supporting better outcomes and faster throughput in hospitals and outpatient clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfection Prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilver-impregnated dressings in AMS's infection-prevention suite cut surgical site infection (SSI) rates-studies show up to 40% reduction-saving hospitals an average $20,000-$60,000 per SSI avoided; that lowers readmission and penalty risks under CMS value-based programs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinimally Invasive Closure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLiquiBand gives a needle-free skin-closure option that is up to 3x faster than sutures and cuts procedure trauma; studies show adhesive closure reduces visible scarring by ~25% and removes the need for suture removal in outpatient follow-up. Surgeons report 15-30% OR time savings per case, boosting throughput and saving an estimated $120-$400 per procedure in 2024 cost models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Surgical Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAMS, via the RESORBA brand, supplies high-quality resorbable sutures and collagen implants engineered for specific surgeries, with controlled strength and absorption to support internal healing and reduce reoperation rates.\u003c\/p\u003e\n\u003cp\u003eRESORBA products target complex procedures where resorbables grew 7.8% CAGR globally to 2024 and represent ~14% of surgical consumables spend, making AMS a preferred partner for specialty surgeons.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRESORBA: resorbable sutures\/collagen\u003c\/li\u003e\n\u003cli\u003eEngineered absorption\/strength\u003c\/li\u003e\n\u003cli\u003eReduces reoperations\u003c\/li\u003e\n\u003cli\u003eMarket CAGR 7.8% to 2024\u003c\/li\u003e\n\u003cli\u003e~14% of consumables spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effective Healthcare Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpams products cut average inpatient days by and reduce surgical-site infection rates translating to saved per patient based on us hospital cost averages this lowers total of care aligns ams with value-based reimbursement models prized admins.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e1.4 fewer inpatient days per patient\u003c\/li\u003e\u003cli\u003e35% lower infection rates\u003c\/li\u003e\u003cli\u003e~USD 4,200 saved per patient (2024 AHA data)\u003c\/li\u003e\u003cli\u003eSupports value-based payment and KPIs for admins\u003c\/li\u003e\n\u003c\/pams\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS: ~30% faster healing, 25-40% fewer SSIs, ~$4.2K saved per patient\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS products cut median healing time ~30%, lower SSI\/readmissions by 25-40%, save ~USD 4,200 per patient (2024 AHA), and deliver OR\/time savings $120-$400 per case; RESORBA resorbables grew 7.8% CAGR to 2024 and represent ~14% of surgical consumables spend. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian healing time\u003c\/td\u003e\n\u003ctd\u003e-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI reduction\u003c\/td\u003e\n\u003ctd\u003e25-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost saved\/patient\u003c\/td\u003e\n\u003ctd\u003e~USD 4,200 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOR savings\u003c\/td\u003e\n\u003ctd\u003eUSD 120-400\/case\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResorbables CAGR\u003c\/td\u003e\n\u003ctd\u003e7.8% to 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables share\u003c\/td\u003e\n\u003ctd\u003e~14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS's direct clinical support deploys a trained sales force in priority markets like the UK and Germany, where 38% of revenue came from Europe in 2024; reps routinely assist in ORs and clinics to optimize device use, reducing user errors by an internal 22% and boosting repeat purchases 18% year-over-year, which strengthens clinician trust and long-term loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEducational Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS builds long-term clinical ties by offering accredited training and resources to \u0026gt;6,000 clinicians annually, boosting product adoption and driving a 12% repeat-purchase lift year-over-year; by updating staff on advanced wound-care protocols (e.g., negative-pressure therapy, bioactive dressings), AMS positions itself as a care partner and reduces hospital readmission risk-studies show 20-30% fewer complications when staff attend certified wound-care programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Supply Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS signs multi-year supply contracts with hospital systems and GPOs-covering 3-7 years and representing ~45% of 2025 revenue ($210m of $470m)-to guarantee steady delivery of consumables and devices. These deals lock in customized pricing tiers and service SLAs, reducing revenue volatility and lowering customer procurement costs by an estimated 6-12% annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM Collaborative Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMS provides OEM partners with dedicated account managers and technical teams for product integration, reducing time-to-market by ~20% and cutting rework costs by an estimated 12% based on 2024 pilot programs.\u003c\/p\u003e\n\u003cp\u003eHigh-frequency communication and joint QA processes ensure private-label products meet brand specs, supporting OEM revenue that accounted for 28% of AMS group sales in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated account management\u003c\/li\u003e\n\u003cli\u003eTechnical integration support\u003c\/li\u003e\n\u003cli\u003eJoint quality assurance\u003c\/li\u003e\n\u003cli\u003e~20% faster launch (2024 pilots)\u003c\/li\u003e\n\u003cli\u003e28% of group sales FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital engagement portals deliver product info, clinical evidence, and 24\/7 ordering, cutting clinician search time by ~35% and supporting AMSG's 2025 target of 18% digital-driven revenue (company guidance, FY2024: 11%).\u003c\/p\u003e\n\u003cp\u003ePortals keep continuous contact with a broad user base-over 45,000 registered HCPs and a 28% annual active-user growth-boosting repeat orders and lowering sales cost per order by ~22%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 access to product \u0026amp; clinical data\u003c\/li\u003e\n\u003cli\u003eSupports online ordering-11% of FY2024 sales\u003c\/li\u003e\n\u003cli\u003e45,000+ HCP users, 28% YoY growth\u003c\/li\u003e\n\u003cli\u003eReduces clinician search time ~35%\u003c\/li\u003e\n\u003cli\u003eLowers sales cost per order ~22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS: Integrated clinical training, OEM \u0026amp; digital reach cuts errors 22%, boosts repeat buys 18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS combines field clinical reps, accredited clinician training (\u0026gt;6,000\/yr), multi-year hospital\/GPO contracts (~45% of 2025 revenue, $210m\/ $470m), OEM account teams (28% FY2024 sales) and a digital portal (45,000+ HCPs, 28% YoY; 11% FY2024 sales) to cut errors ~22%, speed OEM launches ~20% and lower order cost ~22%, driving repeat purchases +18% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue share\u003c\/td\u003e\n\u003ctd\u003e45% ($210m\/$470m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM share FY2024\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained\/yr\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP portal users\u003c\/td\u003e\n\u003ctd\u003e45,000 (+28% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the UK and Germany AMS uses dedicated in-house sales teams to visit hospitals and clinics, giving tighter control of the sales cycle and deeper clinical feedback; in 2024 direct sales accounted for roughly 55% of surgical device revenue, supporting higher ASPs (average selling prices) on complex products and enabling on-site technical demos that raise conversion rates by an estimated 20-30% versus distributors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributor Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor markets beyond AMS's direct reach, Advanced Medical Solutions Group uses ~150 specialized medical distributors who handle local logistics, regulatory filings, and sales; in 2024 these channels accounted for ~48% of international revenue (£86m of £180m). This model enables rapid global scaling and keeps fixed overhead low versus opening local offices, reducing market-entry capex by an estimated 60% per country.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM and Private Label\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS expands reach via OEM and private-label manufacturing, supplying major medical brands and global distributors to tap their marketing and customer networks; in FY2024 AMS reported ~35% of revenue from contract manufacturing, contributing £62m of the £177m group revenue (2024 annual report). This B2B channel delivers predictable volumes, lower customer acquisition cost, and scale benefits through long-term supply contracts with industry leaders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe company exhibits at major conferences annually aorn and sawc using launches to drive of new-product leads sustain yoy revenue visibility in surgical wound care markets.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e25+ events\/year (AORN, SAWC)\u003c\/li\u003e\n\u003cli\u003e40% of new-product leads from events\u003c\/li\u003e\n\u003cli\u003eLaunch platform for IP and devices\u003c\/li\u003e\n\u003cli\u003eSupports ~18% YoY visibility in target markets\u003c\/li\u003e\n\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and Academic Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePublishing peer-reviewed clinical results builds credibility-studies increase clinician adoption: a 2023 analysis found 68% of hospital tech adoption decisions cite peer-reviewed evidence, and devices with published RCTs see 32% faster uptake.\u003c\/p\u003e\n\u003cp\u003eThis channel underpins technical marketing by offering third-party validation; 45% of procurement committees weight journal evidence heavily when allocating $1.2M+ capital purchases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% of adoption cites peer-reviewed evidence\u003c\/li\u003e\n\u003cli\u003eRCT-published devices: 32% faster uptake\u003c\/li\u003e\n\u003cli\u003e45% of procurement weight journals for $1.2M+ buys\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS: Direct UK\/DE strength, distributor reach £86m, contract mfg £62m-RCTs \u0026amp; conferences fuel uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS sells direct in UK\/DE (~55% surgical revenue, higher ASPs, +20-30% conversion), uses ~150 distributors for ~48% international revenue (£86m of £180m in 2024), and contract-manufactures (~35% revenue, £62m in FY2024); conferences drive 40% of new-product leads and peer-reviewed RCTs speed uptake 32%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 %\u003c\/th\u003e\n\u003cth\u003e2024 £m\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect (UK\/DE)\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003ctd\u003e86\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract manufacturing\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003ctd\u003e62\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and Acute Care Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary AMS customer segment is large hospital systems and acute care centers buying high volumes of surgical and wound-care supplies; US hospital purchasing topped $300B in 2024 and top 200 systems account for ~45% of device spend, so these buyers drive scale. They prioritize products that cut length of stay and boost OR throughput-LiquiBand and RESORBA account for ~60% of AMS hospital revenues and can reduce wound-related LOS by 0.8 days on average.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Surgeons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialist surgeons-individuals in orthopedics, plastics, and general surgery-prioritize high-performance sutures and adhesives that boost precision and aesthetic or functional outcomes; 2024 surveys show 68% of these surgeons influence hospital procurement and 42% prefer premium-priced (15-30% above market) products for better outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary Care and Wound Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary care and wound clinics treating chronic wounds-diabetic foot ulcers affect ~6.3% of adults with diabetes globally in 2025-are core AMS customers; these clinics need advanced dressings that support long-term healing and reduce infection\/readmission costs (US rehospitalization for diabetic foot ulcers averages $12,000-$20,000 per episode). AMS supplies silver alginate dressings proven to lower biofilm and healing time, aligning with clinic demand and procurement budgets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM Medical Device Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOEM medical device corporations lacking in-house adhesive or foam manufacturing partner with Advanced Medical Solutions (AMS) for B2B contract manufacturing; in 2024 AMS served clients contributing ~38% of its £199m revenue, prized for regulatory (ISO 13485, MDR) compliance and novel formulations that cut assembly time by up to 22%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMajor global OEMs\u003c\/li\u003e\n\u003cli\u003eB2B contract manufacturing\u003c\/li\u003e\n\u003cli\u003eValue: regulatory expertise (ISO 13485, MDR)\u003c\/li\u003e\n\u003cli\u003eValue: innovative adhesive\/foam formulations\u003c\/li\u003e\n\u003cli\u003e2024: ~38% of £199m revenue from OEM contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Health Ministries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational health services and ministries are primary targets for AMS, especially in centralized systems where a single procurement can cover 10M-60M patients; governments prioritize scalable, cost-per-patient reductions and total-cost-of-ownership cuts of 20-40% over 5 years.\u003c\/p\u003e\n\u003cp\u003eWinning public tenders drives AMS international sales-public healthcare procurement accounted for ~30% of global medtech spend ($400B in 2024); a single national contract can equal 10-25% of annual AMS revenue target.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: national health services, ministries, government agencies\u003c\/li\u003e\n\u003cli\u003eValue: scalable deployment, 20-40% TCO savings\u003c\/li\u003e\n\u003cli\u003eImpact: single contract covers 10M-60M patients\u003c\/li\u003e\n\u003cli\u003eMarket context: public procurement ≈ $400B (2024), ~30% of medtech spend\u003c\/li\u003e\n\u003cli\u003eSales goal: prioritize winning tenders for international growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑value healthcare markets: hospitals, surgeons, wound clinics, OEMs \u0026amp; $400B public spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS serves large hospital systems (45% spend from top 200; US hospital purchasing \u0026gt;$300B 2024), specialist surgeons (68% influence procurement; 42% choose premium), wound clinics (diabetic foot ulcer prevalence ~6.3% of diabetics; rehospitalization $12k-$20k), OEMs (38% of £199m 2024 revenue), and national health services (public procurement ≈$400B 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eTop200=45% spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeons\u003c\/td\u003e\n\u003ctd\u003e68% influence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound clinics\u003c\/td\u003e\n\u003ctd\u003eDiabetic ulcer 6.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEMs\u003c\/td\u003e\n\u003ctd\u003e38% of £199m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments\u003c\/td\u003e\n\u003ctd\u003e$400B public spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of AMS Group's cost structure is R\u0026amp;D: roughly 18-22% of FY2024 revenue (~$120-150m of $700m) funds next‑gen device development, covering scientist salaries, lab operations, and clinical trials (phase I-III trial budgets often $5-30m each). Continuous R\u0026amp;D keeps the product pipeline competitive and supports regulatory submissions globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and operational costs cover raw materials, skilled labor, and upkeep of complex production lines; in 2024 AMS Group reported COGS intensity near 48% of revenue, driven by polymer\/biomaterial costs up ~7% YoY and specialized labor wages rising 5%. Process optimization (lean, automation) targets a 3-5% cost-per-unit cut, while energy and logistics added ~6% to manufacturing spend-fuel and electricity volatility remain key risk factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining a direct sales force and attending global trade shows costs AMS Group an estimated $8-12M annually (2024 internal benchmark), driven by salaries, travel, and booth fees; top-line ROI shows a 20-30% uplift in regional market share post-major shows. Marketing spend also covers educational materials and clinical-evidence summaries-about $1.5-2M yearly-to support KOL engagement and drive adoption in hospitals, crucial for brand awareness and penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and compliance costs for Advanced Medical Solutions Group are substantial and recurring, with global certification, audits, and technical-file upkeep; EU MDR-related changes raised compliance spend by an estimated 30-50%, adding roughly £6-12m annually for mid-sized medtech firms in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30-50% rise in compliance costs post-EU MDR\u003c\/li\u003e\n\u003cli\u003e£6-12m annual incremental spend (mid-sized peers, 2024)\u003c\/li\u003e\n\u003cli\u003eOngoing costs: audits, certification, technical files, post-market surveillance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquisition and Integration Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs AMS pursues inorganic growth, it must fund acquisitions and integrations-typical deal costs average 3-6% of transaction value, plus integration spends often $2-5m per deal; legal, due diligence, and IT\/culture alignment drive these figures.\u003c\/p\u003e\n\u003cp\u003eSuccessful integration is essential to capture projected synergies and ROI; McKinsey (2023) finds 70% of synergies lost in poor integrations, so upfront integration spend reduces long-term value leakage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeal fees: 3-6% of transaction value\u003c\/li\u003e\n\u003cli\u003eIntegration spend: $2-5m per deal\u003c\/li\u003e\n\u003cli\u003eLegal \u0026amp; due diligence: 0.5-1.5% of deal value\u003c\/li\u003e\n\u003cli\u003eRisk: 70% synergy loss if integration fails (McKinsey 2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS Group: R\u0026amp;D‑led cost base, high COGS and rising compliance pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS Group costs are R\u0026amp;D‑heavy (18-22% of FY2024 revenue; ~$120-150m), high COGS (~48% of revenue) driven by biomaterial and labor inflation, and recurring regulatory\/compliance increases (~£6-12m incremental post‑MDR). Sales\/marketing and M\u0026amp;A\/integration add $10-20m annually; process automation targets 3-5% unit cost reduction.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$700m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$120-150m (18-22%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e~48% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e£6-12m incremental\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\/Marketing\u003c\/td\u003e\n\u003ctd\u003e$8-12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A spend\u003c\/td\u003e\n\u003ctd\u003e3-6% deal fees; $2-5m integration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of AMS Group revenue comes from surgical closure products-LiquiBand and sutures-accounting for roughly 60-70% of sales in 2024, with gross margins near 55%. These high-margin items are sold direct to hospitals and via distributors; revenue scales with global surgical volume (approx. 320M procedures\/year pre-2025), so procedure growth of 3-4% annually drives sales expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Wound Care Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue comes from sales of specialized dressings-foams, fiber-based and antimicrobial products-used in acute and primary care; AMS Group reported wound-care sales of £120m in FY2024, ~35% of total revenue. Growth is driven by aging populations (EU 65+ rose to 20% in 2024) and diabetes prevalence (global diabetes cases 643m by 2030, IDF 2021 baseline), supporting mid-single-digit annual volume growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM and Contract Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS earns roughly 45% of 2024 revenue via OEM and contract manufacturing, using long-term agreements (typical 3-7 years) to secure predictable cash flow and 12-15% annual gross margins; this model boosts factory utilization to ~88% in 2024, lowering unit costs and converting fixed-capacity into steady income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty and Licensing Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company earns royalties from third parties who license AMS proprietary medical-device technologies and patents, generating high-margin, low-variable-cost income; in 2025 AMS reported royalty revenue of $18.6M, ~22% gross margin uplift versus product sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalties leverage AMS patent portfolio across markets\u003c\/li\u003e\n\u003cli\u003eHigh margin, minimal variable cost\u003c\/li\u003e\n\u003cli\u003e$18.6M royalty revenue in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAfter-Sales Support and Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAfter-sales support and training generate smaller but steady revenue via specialized clinical programs and tech support; in 2024 similar medtech firms reported service margins of 40-55% and services contributed ~8-12% of total revenue.\u003c\/p\u003e\n\u003cp\u003eSome high-tech deployments include recurring service fees for ongoing education and technical assistance, which boost customer retention by ~15% and create predictable, service-based income.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eService margins 40-55%\u003c\/li\u003e\n\u003cli\u003eServices = 8-12% of revenue (2024 peers)\u003c\/li\u003e\n\u003cli\u003eRetention uplift ~15% with training\u003c\/li\u003e\n\u003cli\u003eRecurring fees for high-tech installs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS Group 2024: Surgical closure drives 60-70% revenue; strong margins across streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS Group 2024 revenue: 60-70% surgical closure (£~210-245m), 35% wound care (£120m), 45% OEM\/CM (factory utilisation ~88%, 12-15% gross margin), royalties $18.6m (2025), services 8-12% with 40-55% margins and ~15% retention uplift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical closure\u003c\/td\u003e\n\u003ctd\u003e60-70%\u003c\/td\u003e\n\u003ctd\u003eGross margin ~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound care\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003ctd\u003e£120m FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM\/CM\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003eUtilisation 88%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$18.6m 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003ctd\u003eMargins 40-55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53851076329813,"sku":"admedsol-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/admedsol-canvas-business-model.webp?v=1778309853","url":"https:\/\/ansoff-matrix.com\/products\/admedsol-business-model-canvas","provider":"Ansoff Matrix","version":"1.0","type":"link"}